homepage-top-section

Onpattro is claimed to be the first-of-its-kind RNAi therapeutic and only FDA-approved treatment for this indication. Earlier, Onpattro secured breakthrough therapy and orphan drug designations from the FDA.

Millendo is engaged in the development of novel treatments for orphan endocrine diseases. The combined company will further advance Millendo’s pipeline of transformative treatments for orphan endocrine diseases.

The partnership announcement coincided with official launch of Ambys Medicines with a $60m Series A financing funded by Third Rock Ventures and Takeda. The partnership with Takeda brings

The marketing authorization has been granted for Xeljanz10 mg twice-daily (BID) for at least eight weeks, followed by Xeljanz 5mg BID or 10 mg BID, to treat adult

Included in the acquisition are branded topical prescription treatments for acne, fungal skin infections and rosacea, along with a variety of topical steroids, which had an annual turnover

The company expects to invest up to $200m in the approximately 120,000ft² biomanufacturing plant at its West Greenwich campus in Rhode Island. Amgen will use its next-generation biomanufacturing

The approval is for the intravenous use of the Azedra injection in patients whose adrenal gland tumors are unresectable and have spread beyond the original tumor site and

The company has announced the positive top-line safety and efficacy results from the MAP US study, which showed superiority of RHB-104 over placebo. RHB-104 is a proprietary and

It is the fourth Sandoz biosimilar approved in Europe in past 18 months, and seventh in total. Hyrimoz is an inhibitor of tumor necrosis factor (TNF), a protein